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Purpose: Purpose:Recent public health safety issues involving medical devices have
led to a growing demand to improve the current passive‐reactive postmarketing sur-
veillance (PMS) system. Various European Union (EU) national competent authorities
have started to focus on strengthening the postmarket risk evaluation. As a conse-
quence, the new EU medical device regulation was published; it includes the concept
of a PMS Plan
Methods: This publication reviewed Annex III Technical Documentation on PMS
and Annex XIV Part B: Postmarket clinical follow‐up from the new Regulation (EU)
2017/745 of the European Parliament and of the Council on medical devices.
Results: The results of the PMS activities will be described in the PMS plan and will
be used to update other related documents. A modular approach to structure the
contents of the PMS plan will help to consistently update other PMS information. It
is our suggestion that the PMS plan should consist of a PMS plan Core and a PMS
plan Supplement. The PMS plan Core document will describe the PMS system, and
the PMS plan Supplement will outline the specific activities performed by the manu-
facturer for a particular medical device.
Conclusions: The PMS plan may serve as a thorough tool for the benefit‐risk eval-
uation of medical devices. If properly developed and implemented, it will function as a
key player in the establishment of a new framework for proactive safety evaluation of
medical devices.
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evaluation1 | INTRODUCTION
A medical device is defined as “any instrument, apparatus, appliance,
material, or other article, whether used alone or in combination,
including the software necessary for its proper application intended- - - - - - - - - - - - - - - - - - - - - - - - - -
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KEY POINTS
• The new European Union (EU) postmarketing
surveillance (PMS) plan may serve as a thorough tool
for the benefit-risk evaluation of medical devices.
• If properly developed and implemented, the EU PMS plan
will function as a key player in the establishment of a new
framework for proactive safety evaluation of medical
devices.
2 PANE ET AL.Recent public health safety issues involving medical devices have
highlighted the need to update the European Union (EU) medical device
regulation (MDR). The Poly Implant Prothèse (PIP) breast implant scan-
dal in 2012 affected thousands of women and damaged the confidence
of the different stakeholders involved in postmarket surveillance (PMS)
of medical devices.2 More than 400 000 women around the world
received PIP implants that were made of industrial‐grade silicone gel,
prone to rupture, leading to inflammation and irritation. Another inci-
dent in 2012 involving hip implants raised a public health concern:
metal‐on‐metal total hip replacements were successfully implanted,
but metal abrading against metal caused erosion and leaching of metal
particles into soft tissue.3 Such metal debris weakens tissue and bone
around the implant, leading to implant failure, requiring additional sur-
gery. The manufacturers did not provide an adequate response to the
competent authorities with regard to these adverse events and there
was always the belief that they could have been avoided.4
As a consequence, various national competent authorities (NCAs)
and other health organizations started focusing on strengthening
postmarket risk evaluation of medical devices. One of the important
novelties in the new regulation on medical devices (EU) 2017/745,
published May 5, 2017 is the concept of a PMS Plan for each medical
device family.5 A regulation is a legal act of the EU that becomes
immediately enforceable as law in all member states simultaneously.
Regulations can be distinguished from directives which, at least in
principle, need to be transposed into national law.6 The current
Medical Device Directive (MDD) 93/42/EEC states that “The manu-
facturer shall institute and keep up to date a systematic procedure
to review experience gained from devices in the post‐production
phase, including the provisions referred in Annex X, and to implement
appropriate means to apply any necessary corrective action.” Annex X
says that “The clinical evaluation and its documentation must be
actively updated with data obtained from the PMS. Where a
postmarketing clinical follow‐up as part of the PMS plan for the device
is not deemed necessary, this may be duly justified and documented.”7
Contrary to what happens with the new regulation, there are no
instructions or guidance on the contents of the PMS plan and on
how to implement this requirement in the current MDD 93/42/EEC
although the concept of a PMS plan is mentioned.
According to the new regulation, the PMS Plan will have to define
the process for collecting, recording, and investigating complaints and
reports from health‐care professionals, patients, and users on events
suspected to be related to a medical device. A PMS system that is
correctly designed should allow for early detection of possible
malfunctions and/or complications of medical devices that may occur
only after years or even decades of usage and implement appropriate
risk minimization measures.
Today, many medical device manufacturers have a “reactive” PMS
system that is based on collection of postmarket data received from
spontaneous reporting of complaints and incidents. Unfortunately, there
are few proactive PMS processes designed to actively gain knowledge
on the safety and performance of the medical device through external
sources like registries, electronic health‐care records, safety evaluation
sites, claim databases, social networks, and literature.8The new EU Regulation aims to reinforce key elements of the
existing regulatory approach, including vigilance and market surveil-
lance, at the same time ensuring transparency and traceability, to
improve health and safety.5 The objective of this article is to describe
the new EU Regulation on PMS of medical devices, to compare it with
our experience in the drug area, and to provide recommendations for
implementation.2 | PMS SYSTEM FOR MEDICINAL
PRODUCTS AND MEDICAL DEVICES IN
THE EU
2.1 | Medicinal products
Manufacturers may submit a marketing authorization application to
either European Medicines Agency (EMA) or to the NCAs of the mem-
ber states. Authorization through the European Medicines Agency,
also known as the centralized procedure, offers the benefit of a single
assessment process and a marketing authorization valid throughout
the European Economic Area. Authorization through the centralized
procedure is mandatory for innovative medicines derived from bio-
technology, orphan medicines, and new active substances for the
treatment of acquired immunodeficiency syndrome, cancer, neurode-
generative diseases, diabetes mellitus, autoimmune diseases and other
immune dysfunctions, and drugs targeting viral diseases.9
Similarly to medical devices, safety issues involving medicinal prod-
ucts showed a need for a more proactive risk management approach of
medicinal products. This led to the development of the International
Conference on Harmonisation of Technical Requirements for Registra-
tion of Pharmaceuticals for HumanUse (ICH) E2E guidance on riskman-
agement planning. This guidance was implemented in EU regulation in
2005 in the form of the EU risk management plan (EU‐RMP), which is
a mandatory template document for the authorization dossier of inno-
vative drugs licensed in the EU.10-12 The EU‐RMP describes the impor-
tant risks and areas of missing information, the activities intended to
further characterize the safety profile, and the measures to minimize
the risks.13,14 The EU‐RMP is updated throughout the product life cycle
as studies are completed or new information becomes available that
may change the benefit‐risk balance.15 Significant variation exists in
the requirements and execution of postauthorization safety studies
TABLE 1 Lessons learned from the pharmaceutical world and recommendations for implementation of the PMS plan for medical devices
Topic Lessons Learned from the Pharmaceutical World
Recommendations for Implementation of the PMS Plan
for Medical Devices
Enforcement of postapproval
commitments
PRAC has played a key role to centralize all efforts to design
and evaluate PASS; PRAC has been instrumental to
enforce postapproval commitments related to PASS.
As part of the NB's oversight, there should be a centralized
group responsible for monitoring and assessing the
safety of medical devices. This group should include CA
and notified bodies and should enforce the completion
of CE mark commitments, such as postmarket studies or
registries included in the postmarket clinical follow‐up
plan.
Documentation, monitoring,
and enforceability of
postapproval
commitments
Implementation of the EU‐RMP template triggered more
proactive approaches and the documentation of many
additional risk minimization activities. Enforceability of
these postapproval commitments came from making
these commitments conditions to the marketing
authorization of the medicinal product.
Implementation of an actual PMS plan template is also
important to document the postapproval commitments
(eg, postmarket studies and risk minimization activities).
Enforceability of these postapproval commitments will
come from making these commitments conditions to the
marketing authorization of the medical device and
verification during the annual PMS audits performed by
the notified body.
Inclusion of risks in the PMS
documents
Only important risks (risks that have an impact on the
benefit‐risk balance) from the safety specification should
be included into the PV plan.
Regulator‐led initiative to develop risk based approach
guidances to recommend the inclusion of only important
risks (risks that have an impact on the benefit‐risk
balance) in the PMS documents (based on ISO 14971).
Due to the wide range of medical devices and the
different levels of complexity, these documents should
be product‐specific.
Manufacturer's
organizational adaptation
Cross‐functional review of the risk minimization programs
and inclusion of senior management in final approval is
recommended.
Cross‐functional review of the PMS plan is
recommendable. The final approval of the PMS plan
should be made by the PRRC within the company.
Abbreviations: EU, European Union; NB, notified body; PASS, postauthorization safety studies; PRAC, Pharmacovigilance Risk Assessment Committee;
PMS, postmarketing surveillance; PRRC, person responsible for regulatory compliance; RMP, risk management plan; PV, pharmacovigilance.
TABLE 2 PMS System: comparison between the current MDD7 vs
the new MDR5
MDD PMS Key Principles
MDR Additional PMS
Requirements
Compared with MDD
Systematic procedure to review
experience gained from the
market.
PMS oversight: notified bodies and
competent authorities have
increased postmarket surveillance
authority for unannounced
audits, samples checks, and
annual safety reports.
Obligation to report incidents and
increase in trends.
Clinical Evidence: Manufacturers
need to conduct clinical
investigations and collect
postmarket clinical data as part of
ongoing safety assessment.
PMCF plan to be part of the PMS
plan. One PMS plan and one
PSUR per device/device group/
family.
PANE ET AL. 3(PASS) and additional risk minimization measures.16-19 This is partly
because the EU‐RMP is product‐specific and strategies are tailored to
be risk‐proportionate (ie, taking into account variables such as serious-
ness and severity of the risk, target population, and health‐care setting
of use of the product).20 However, some variation is also due tomarket-
ing authorization holders: there is no gold standard for an optimal risk
management organizational structure, and it depends on the magnitude
and complexity of the company's pipeline, economic and staffing limita-
tions, and organizational commitment to patient‐centeredness.21
Cross‐functional review of the risk minimization programs is recom-
mendable and inclusion of senior management in final approval. The
Pharmacovigilance Risk Assessment Committee (PRAC), an EMA scien-
tific committee responsible for the review of all aspects of risk manage-
ment planning, has been instrumental to overseeing postapproval
commitments, and has played a key role in centralizing all the efforts
to design and evaluate PASS .22 Table 1 describes some of the lessons
learned from the pharmaceutical world and provides recommendations
for implementation of the PMS plan for medical devices.Abbreviations: MDD, Medical Device Directive; MDR, medical device reg-
ulation; PMCF, the postmarket clinical follow‐up; PMS, postmarketing sur-
veillance; PSUR, periodic safety update report.2.2 | Medical devices
NCAs, notified bodies (NBs), and manufacturers are all involved in
the European Conformity (CE) marking process that allows marketing
of a medical device in the EU. The NB is an entity that has beenaccredited by an EU member state to assess whether a manufac-
turer's quality management system procedures and product technical
documentation meets certain standards described in the EU MDD.
TABLE 3 Medical device vigilance system: comparison between Meddev 2.12‐125 vs the new MDR5
Topic Meddev 2.12‐1 MDR
What to report? • Near incident (serious) • Serious incidents
• Serious incident
Reporting timelines • Serious public health threat: 2 days • Serious public health threat: 2 days
• Death or unanticipated serious deterioration in state of
health: 10 days
• Death or unanticipated serious deterioration in state of
health: 10 days
• Other reportable incidents: 30 days • Other serious incidents: 15 days
Periodic summary reports When agreed with the coordinating CA: When agreed with the coordinating CA:
• For similar incidents with known root cause or FSCA
implemented
• For similar incidents with known root cause or FSCA
implemented
• For common, well documented incidents • For common, well‐documented incidents
Report to • NCA • Centralized electronic reporting in EUDAMED
Trend reporting Trend reporting is used by the manufacturer when a
significant increase in events not normally considered to
be incidents and for which predefined trigger levels are
used to determine the threshold for reporting.
Mandatory reporting of:
• Statistically significant increase in frequency or severity
of non‐serious incidents or expected side‐effect that
could impact risk/benefit ratio
• ‘statistically significant increase’ needs to be defined
upfront in theTech File as part of the PMS plan for the
device
The EU Commission will perform trending and signal
detection based on the data in Eudamed.
FSCA • The details of FSCAs are communicated by
manufacturers to the NCAs via FSCA form and to the
users in FSNs.
• The details of FSCAs are communicated by
manufacturers to the NCAs via FSCA form and to the
users in FSNs.
• The NCA may perform their own risk assessment,
manufacturer has to provide the supporting
documentation.
• The NCA may intervene in the manufacturer's
investigation.
• The FSN needs to contain the UDI and the
manufacturer's SRN and needs to be uploaded in
Eudamed.
NCAs may ask manufacturers for corrective actions and
will inform the NB, other manufacturers and the EU
Commission.
PSUR Not included in the current guideline. • Class I devices: PMS report updated when necessary,
but at least every 5 years.
• Class IIa: PSUR to be updated when necessary, but at
least every 2 years.
• Class IIb (non‐implantables): PSUR to be updated
annually.
• Class IIb (implantables), III: PSUR to be updated
annually and sent to the NB for evaluation.
• Analysis of PMS data.
• Description of preventive and corrective actions.
• Conclusion of the benefit/risk evaluation.
• Main findings of the PMCF report.
• Sales volumes, estimate of the population using the
device, usage frequency of the device.
Abbreviations: CA, competent authority; EU, European Union; EUDAMED, European Database on Medical Devices; FSCA, field safety corrective action;
FSN, field safety notice; MDR, medical device regulation; NB, notified body; NCA, national competent authority; PMCF, postmarket clinical follow‐up;
PSUR, periodic safety update report; UDI, unique device identifier.
4 PANE ET AL.With the NB's certificate, the manufacturer can then issue the decla-
ration of conformity, and apply the CE Mark, which is required for
sale in the EU. The conformity assessment can include inspection
and examination of a product, its design, and the manufacturingenvironment and processes associated with it, including the safety
evaluation of the medical device.
NCA's exist in each European member state and are nominated by
each government to monitor and ensure compliance with its
TABLE 4 Essential requirements from the EU regulation for medical devices that are relevant to the technical documentation on postmarket
surveillance – Extract of the EU regulation.5
EU MDR (Annex III Technical Documentation on Postmarket Surveillance):
The manufacturer shall prove in a postmarket surveillance plan that it complies with the obligation referred to in Article 83
(a) The postmarket surveillance plan shall address the collection and utilization of available information, in particular:
‐ Information concerning serious incidents, including information from PSURs, and FSCAs;
‐ Records referring to non‐serious incidents and data on any undesirable side‐effects;
‐ Information from trend reporting;
‐ Relevant specialist or technical literature, database and/or registers;
‐ Information, including feedbacks and complaints, provided by users, distributors, and importers; and
‐ Publicly available information about similar medical devices;
(b) The postmarket surveillance plan shall include at least:
‐ A proactive and systematic process to collect any information referred to in point (a). The process shall allow a correct characterization of the
performance of the devices and shall also allow a comparison to be made between the device and similar products available on the market;
‐ Effective and appropriate methods and processes to assess the collected data;
‐ Suitable indicators and threshold values that shall be used in the continuous reassessment of the risk benefit analysis and of the risk management as
referred to in Section 3 of Annex I;
‐ Effective and appropriate methods and tools to investigate complaints or market experiences collected in the field;
‐ Methods and protocols to manage the events subject to trend report as provided for in Article 88, including the methods and protocols to be used to
establish any statistically significant increase in the frequency or severity of incidents as well as the observation period;
‐ Methods and protocols to communicate effectively with competent authorities, notified bodies, economic operators, and users;
‐ Reference to procedures to fulfil the manufacturers obligations laid down in Articles 83, 84, and 86;
‐ Systematic procedures to identify and initiate appropriate measures including corrective actions;
‐ Effective tools to trace and identify devices for which corrective actions might be necessary; and
‐ A PMCF plan according to in Part B of Annex XIV, or a justification why a PMCF is not applicable.
Abbreviations: FSCA, field safety corrective action; PMCF, postmarket clinical follow‐up; PSUR, periodic safety update report.
FIGURE 1 Overview of the main differences during new product development between medical devices and medicines [Colour figure can be
viewed at wileyonlinelibrary.com]
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FIGURE 2 The medicinal product and the medical device development pathway in the EU. *Not always mandatory. Note. Some low risk (class I)
medical devices may be “self certified” (without requiring a CE certificate from the notified body [NB])26 [Colour figure can be viewed at
wileyonlinelibrary.com]
FIGURE 3 Risk managements documents required for the market placement of a medical device compared with a medicinal product. *It includes
description of processes and metrics. **Does not include description of processes and metrics. This information is included in the
pharmacovigilance system master file (PSMF). Note: In the European Union (EU), some low risk (class I) medical devices may be “self certified”
(without requiring a CE certficate from the notified body [NB])26 [Colour figure can be viewed at wileyonlinelibrary.com]
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TABLE 5 Suggested template: PMS plan Core
1. PMS
Data source All data source for that medical device
Complaint management (this would be part of the processes subsection) Intake of an adverse event/technical complaint
Medical review
QA product investigations
Follow‐up
Submission/reporting process
Customer feedback (subsection of source data) Postmarket clinical follow‐up plan (subsection of processes)
Monitoring of product benefit‐risk profile (subsection of processes) Adverse event trending
Technical complaint trending
Postproduction information
Risk management (subsection of processes) Field action assessment committee
Device medical safety review board
Safety governance review board
2. Risk minimization measures (part of the risk management)
Communication of safety concerns Safety communication process
Effectiveness of risk minimization measures Risk reduction process
Labeling committee Labeling risk minimization measures
3. Other PMS‐related processes and key SOPs
Abbreviation: PMS, postmarketing surveillance; QA, quality assurance; SOP, standard operating procedure.
PANE ET AL. 7provisions of the MDD 93/42/EEC. The NCA designates a NB to
ensure that conformity assessment procedures are completed accord-
ing to the relevant criteria. The authorized representative, designated
by the manufacturers (there is only an authorized representative when
the manufacturer is not based in the EU; when the manufacturer is
based in the EU, the manufacturer is the direct point of contact.), is
legally responsible for compliance with the regulations and acts as
the first point of contact for the EU authorities. It is the manufac-
turer's responsibility to ensure that their product complies with the
essential requirements of the relevant EU legislation. Medical devices
are classified based on the risk associated with them, using the classi-
fication rules listed in Directive 93/42/EEC Annex IX. The categories
are Class I, Class IIa and IIb, and Class III, with Class III ranked as the
highest. The higher the classification, the greater the level of assess-
ment required by NBs. The classification is based on the intended pur-
pose of the device and not the particular technical characteristics.
There are different aspects that are being taken into consideration
for classification: grade of invasiveness, duration of contact with the
body, and local versus systemic effect.7,23
In order to obtain the CE mark that allows marketing of a medical
device in the EU,24 the manufacturer is obliged to identify and
describe the risks detected during the pre‐market phase.1,5 The risk
management file (RMF) of the medical device or its family should con-
tain clear definitions of the hazardous situations associated with use
of the medical device. In addition, it should also describe the potential
harms associated with these situations as well as the applicable risk
minimization measures to avoid or mitigate these harms in both
patients and health‐care users.
According to the new EU MDR for medical devices, a comprehen-
sive RMF demonstrating a positive benefit/risk profile is conditional tomarketing and required to be monitored postmarketing in a timely
manner. The new EU MDR has additional requirements in PMS and
Vigilance compared with the current MDD (Tables 2 and 3). The
new EU MDR states that the PMS plan “shall be suited to the actively
and systematically gathering, recording and analysing relevant data on
the quality, performance and safety of a device throughout its entire
lifetime, and to drawing the necessary conclusions and to determining,
implementing and monitoring any preventive and corrective actions”.5
Table 4 specifies the main technical requirements of the PMS plan.
The final approval of the PMS plan should be made by the person
responsible for regulatory compliance (PRRC) within the company.
To understand the key differences between the flow of risk man-
agement documents for a medical device and a medicinal product, it
is important to understand the main differences between medical
devices and medicines during new product development (Figure 1)
and the main differences during the development pathway
(Figure 2).8 Figure 3 describes the flow of risk management docu-
ments that are required for a medical device and a medicinal product.
One of the key differences between the two products is the filtering
performed for medicinal products: only important risks (risks that
have an impact on the benefit‐risk balance) from the safety specifica-
tion should be included into the pharmacovigilance (PV) plan. For
medical devices, there are no regulatory documents that provide
guidance on filtering the risks from the RMF into the PMS plan.
The RMF of a medical device includes the risk analysis, the risk
evaluation, the implementation and verification of the risk control
measures, and the assessment of the acceptability of any residual
risk. Another difference with regard to medical devices is that the
RMP of a medicinal product needs to be reviewed and approved by
regulatory authorities, whereas the RMF or the PMS plan of a
8 PANE ET AL.medical device are reviewed by the NB and do not require approval
from the NCA. Contrary to what happens with medicinal products
where the process goes through the EMA, or the designated NCA,
in EU, the medical devices do not need to be approved by the
NCA. In EU, the new medical device application (if required) is per-
formed by the NB—an entity that examines the medical device appli-
cation to assure compliance with the EU regulation. If the device
meets regulatory requirements, a CE is applied, and the medical
device can be marketed throughout Europe.26TABLE 6 Suggested template: PMS plan Supplement
1. Product Overview
Product name(s)/family
Approved indication(s)
Population being treated
Medical device risk classification
License partners (if applicable)
2. Summary of Safety Concerns
Safety Concern Hazard Harm
Important identified risks
Important potential risks
Missing information
3. Risk Minimization Measures
Inherent safety by design and construction
Protective measures in the medical device itself or in
the manufacturing process
Training to users and/or information for safe and
proper use
Conduct of a study
Communication of a FSCA
4. Additional PMS Activities
Activity Rationale
5. Plans for PMCF and Clinical Evaluation
Summary of PMCF report (including registry review) and CER
6. Safety Communications
External and internal communication of safety concerns
7. Annexes
Training of Personnel
Documents and Records
8. References
Abbreviations: CER, clinical evaluation report; FSCA, field safety corrective
action; PMCF, postmarket clinical follow‐up; PMS, postmarketing
surveillance.3 | RECOMMENDATIONS FOR
IMPLEMENTATION OF THE PMS PLAN FOR
MEDICAL DEVICES
Most of the current PMS requirements are included in the medical
device guidelines, and not in the current MDD; this has led to enforce-
ment challenges for the manufacturer's requirements. With the new
regulation, the EU wanted to eliminate those challenges and, at the
same time, provide instructions on how to build a more proactive
PMS system (Tables 6 and 7).
Based on the requirements described in the new regulation and the
lessons learned from medicinal products, we would like to propose the
following recommendations for implementation of the new legislation.
We have designed a template for the PMS plan content (see Tables 3
and 4). The PMS plan becomes a master file and consists of a PMS plan
Core (Table 5) and a PMS plan Supplement (Table 6) containing differ-
ent modules of PMS data. The Core document should describe the
PMS system (routine PMS procedures, methodologies, and activities
that are being performed for all medical devices or group/family of
medical devices) as well as the key performance indicators (KPIs) used
to evaluate the effectiveness of the plan. The Supplement should
describe the specific PMS activities, methodologies, and procedures
performed by the manufacturer for a particular medical device or
family/group of medical devices. The PMS Plan shall also define the
frequency of the PMS data review. The manufacturer should institute
a system to assess all the PMS information with a specific frequency
and implement the necessary actions to improve safety and perfor-
mance of the product. The Core and the Supplement should have
different review timelines: the PMS plan Core only describes the pro-
cesses and does not require a continuous update of the content. The
periodicity of renewal of the PMS plan Supplement should be consis-
tent with the risk associated to the product, the innovative character
of the device, and the level of clinical experience with the device. For
example, as a general rule, classes IIb and III medical devices should
be reviewed on a yearly basis and class IIa on a biannual basis
(Note. Class I devices still need a review, but it is a simplified PMS
supplement that should be updated at least every 5 years).
The final approval of the PMS plan should be made by the
PRRC. However, the PMS plan should also define who will review
the PMS plan. We have learned in the drug era that the
manufacturers should create an organizational model that ensures
an efficient cross‐functional review and senior managementcommunication and the systematic incorporation of patient and
health‐care professional's input into the PMS workflow. Key
individuals from the different departments such as Medical Safety,
Clinical, Research and Development, Regulatory Affairs, Compliance
and Quality Assurance should participate in the production of the
Core and Supplemental PMS plan. The final review of the
documents should be performed by a cross‐functional senior
management team.
Prior to launch, the manufacturer shall incorporate the risk minimi-
zation measures. The actual PMS plan and the activities involved with
it may also lead to risk minimization measures such as a change in the
IGURE 4 Output of the postmarketing surveillance (PMS) plan [Colour figure can be viewed at wileyonlinelibrary.com]
PANE ET AL. 9Flabeling, a design change, or a material change. The new risk minimiza-
tion measure will need to be documented in a consistent and timely
manner across the other PMS documents (such as Risk Management
and Periodic Safety Update Reports). This will be ensured by the use
of the suggested modular approach (see Table 6) for the PMS plan
structure.
A program of appropriate PMS including postmarket studies and
registries is very important to detect and investigate risks associated
with the use of marketed medical devices and should be included in
the postmarket clinical follow‐up (PMCF) plan. The plan describes
methods for clinical data collection to confirm the safety and perfor-
mance of a device throughout its lifetime; these methods may include
postmarket studies or registries as appropriate.
Postmarket studies and registries provide information on “real
world” use and are a component of PMS. The postmarket studies
can be sponsor‐led (sponsored by the manufacturer) or investigator‐
initiated trials (IITs) which are any scientific study, other than a
manufacturer‐sponsored study, originated and proposed by a third
party investigator. Medical device registries can be sponsor‐led or
health authority‐mandated and are designed for different purposes.
They can offer valuable data on long‐term effectiveness and safety
of devices or on the impact of factors such as surgical method, physi-
cian, hospital, and patient conditions.27
It is important to take into consideration that data from these stud-
ies and registries need to be used for continuous evaluation of the
benefit‐risk profile as well as for discovery of new indications of use.
When the PMCF study is completed, there should be a final report
with clear conclusions that will be included in the periodic safety
update report (PSUR).
The results of PMS activities will have an impact on the PMSprocess
during the device life cycle management. Some of the information fromthe PMS plan will be used to update other related PMS documents. A
modular approach to structure the contents of the PMS plan may help
to consistently update other PMS information. The output of the PMS
plan could lead/affect different postmarket documents (Figure 4). For
example, after the review of national registries (part of the PMCF up
plan), the manufacturer may identify a new safety issue with the prod-
uct that will affect different postmarket documents: update of RMR,
update of clinical evaluation report (CER), new PSUR, development of
corrective and preventive actions (CAPAs), new training to the user, or
submit a field safety corrective action (FSCA) to the NCA.
To measure the effectiveness of the PMS plan, it is important to
have adequate tools in place for each of the processes. KPIs must be
identified a priori when building the processes. Moreover, together
with the KPIs, it is essential to identify a threshold for each of the indi-
cators to take action if this threshold is reached. Therefore, the key
processes that need to be measured should be identified, and the sig-
nificant points of measurement that define the performance of the
systems should be described in the PMS plan. Thesemeasureswill help
to identify areas of improvement. InTable 7, we propose different KPIs
to monitor the performance of the PMS system, there should be KPIs
for case processing, safety communications, PSURs, risk management,
early detection of signals, and implementation of corrective actions.4 | DISCUSSION
This paper tries to provide implementation guidance to the medical
device EU‐regulation based on lessons learned from the medical prod-
uct area. We have seen how vital it is to identify the risks in a timely
manner for all stakeholders to be aware of the risks associated with
medical devices. Stakeholders need to take appropriate corrective
TABLE 7 Proposed KPIs to measure effectiveness of PMS plan
Process KPI
Type
Quality Timeliness
1. Case
processing
Expedited reporting on time ‐ ✓
Periodic Reporting on time ‐ ✓
2. Case quality
review
Case quality review ✓ ‐
Quality review of regulatory
reports
✓ ‐
Comments and Inquiries
received from CA after the
submission of a regulatory
report
✓ ‐
3. Periodic
search of
scientific
literature
Literature search review
timeliness
‐ ✓
Peer review of selected
abstracts
✓ ‐
Peer review of rejected
abstracts
✓ ‐
4. Aggregate
reports
PSUR submission timeliness to
CAs
‐ ✓
Comments and Inquiries
received from CA after the
submission of PSUR
✓ ‐
5. Safety communications Safety
communications submitted
on time
‐ ✓
Comments and
inquiries from
CAs, health‐
care
professionals,
or consumers
received after
the
submission of
the safety
communications ✓ ‐
6. Signal
detection
Signals detected on time; timely
identification of safety issues
‐ ✓
Signal evaluation and validation
performed effectively; real
signal?
✓ ‐
7. Corrective
action
Corrective actions implemented
on time
‐ ✓
Corrective actions
effectiveness
✓ ‐
8. Risk
management
Risk management file timely
review; timely update of the
risk management file
‐ ✓
Rates of comments and
inquiries from CAs by impact
✓ ‐
Abbreviations: CA, competent authority; KPI, key performance indicator;
PMS, postmarketing surveillance; PSUR; periodic safety update report.
10 PANE ET AL.and preventive measures to improve patient outcome3 resulting in a
device that is safe and performs well.
We conclude that the PMS plan needs to include the identified
risks, potential risks, and missing information from the RMF. Next,
safety evaluation tools (CER, PSUR, RMF) to find responses tounanswered questions and find more information regarding missing
information should be implemented. The PMS plan should have clear
objectives, a robust structure with specifications on data integrity,
periodicity, and defined responsibilities. We recommend a modular
approach to structure the contents of the PMS plan that will facilitate
consistent updating of other PMS information. The PMS plan should
consist of a PMS plan Core and a PMS plan Supplement. The PMS
plan Core document will describe the manufacturer's general PMS
system, and the PMS plan Supplement will describe the specific PMS
activities performed by the manufacturer for a particular medical
device or family/group of medical devices. Since we learned from
the medicinal products area that a template is important, we proposed
one. In addition to the template, another important aspect learned
from the experience with medicinal products is the methodology used
to include customer feedback and the organizational structure within
the company. To deliver high‐quality PMS plans, companies need to
implement a system that includes cross‐functional review and takes
into account the patient feedback received during the postmarket
phase. A difference with medicinal products is the fact that no filtering
is implemented: we would recommend that the regulatory bodies
develop product‐specific guiding documents outlining how to perform
the filtering of risks from the RMF to the PMS plan and also provide
guidance on the stakeholder responsibility in reviewing and approving
the PMS plan.
Moreover, to ensure the success of the PMS plans, the manufac-
turers should first identify the key processes of the plan and define
KPIs as well as the associated thresholds to take action. These
indicators will help to measure the effectiveness of the plan.
In conclusion, the new EU MDR may positively impact medical
device safety evaluations and calls for a more hands‐on approach,
which does not only consist of spontaneous reporting, but also include
proactive methods to manage product‐related risks with new safety
evaluation tools such as the PMS plan. There are several questions
regarding the implementation of the new EU medical device guideline
and differences with medicinal products. This paper tries to review
them and provide some guidance.
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